Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Radiology

The Diagnostic Pathway and Your Biopsy

At a Glance

A breast adenoma diagnosis combines imaging with a core needle biopsy and a check that the tissue result matches the scan. A benign, matching result often leads to monitoring, while a mismatch or concerning feature may require another biopsy or surgical removal.

The journey from finding a breast lump to receiving a final diagnosis involves several distinct steps designed to ensure accuracy. Because a breast adenoma can look very similar to other types of breast lumps—including both common fibroadenomas and, more rarely, certain types of cancer—your medical team uses a combination of imaging and tissue sampling to reach a definitive conclusion.

Step 1: Specialized Imaging

The first step in evaluating a breast lump is usually imaging. The type of test you receive typically depends on your age and the specific characteristics of the lump.

  • Ultrasound: This is often the first-line tool for patients under 30 and those who are currently pregnant or breastfeeding [1][2]. On an ultrasound, a tubular adenoma often appears as a smooth, oval, dark (hypoechoic) mass [3].
  • Diagnostic Mammography: For patients age 30 and older, a mammogram is often added to the assessment (and can still be used during pregnancy or lactation if clinically indicated) [4]. It allows doctors to look for specific patterns, such as calcifications (tiny calcium deposits) or architectural distortion (areas where the breast tissue looks pulled or abnormal) [5][6].

The BI-RADS Score

Radiologists use a standardized system called BI-RADS to communicate how concerned they are about an imaging finding [7].

  • BI-RADS 3: Means “probably benign.” There is less than a 2% chance of cancer, and the standard recommendation is usually short-interval follow-up imaging [8][9].
  • BI-RADS 4: Means “suspicious.” This category is broad (ranging from a 2% to 95% chance of malignancy) and usually requires a biopsy to confirm the diagnosis [10][11].

Step 2: The Core Needle Biopsy

While imaging provides a “picture” of the lump, a core needle biopsy (CNB) looks at the actual cells to help establish the diagnosis [1]. Unlike a fine needle aspiration (FNA)—which only pulls out individual cells—a core biopsy removes small “cores” or cylinders of tissue [12]. This allows the pathologist to see the architecture of the tissue (how the cells are arranged), which is vital for distinguishing an adenoma from a more complex growth [13][14].

However, a core biopsy is not magic. It relies on the needle hitting the right spot. A core sample can occasionally miss a heterogeneous area, which is why the overall clinical picture matters.

Step 3: Radiologic-Pathologic Concordance

The most critical part of your diagnosis is a step called radiologic-pathologic concordance. This is a safety check where your care team asks: “Does the pathology adequately explain the imaging finding, and was the sample representative?” [15].

  • Concordant: If a lump looked like a simple, benign mass on an ultrasound and the biopsy comes back as a “tubular adenoma,” the findings reasonably explain one another. You can usually move to routine monitoring [16].
  • Discordant: If the imaging looked highly suspicious (BI-RADS 4C or 5) but the biopsy only showed “normal breast tissue” or a “benign adenoma,” the results are discordant [17]. Your doctor will likely recommend a repeat biopsy or surgical removal to be sure nothing was missed [16][18].

Understanding Your Pathology Report

Pathology reports use dense medical language. You do not need to diagnose yourself, but reviewing these key concepts with your clinician can be helpful. A typical report for a benign tubular adenoma will assess:

  • Subtype and Diagnosis: The specific name of the lesion (e.g., tubular adenoma).
  • Atypia: The pathologist looks for abnormal cells. The absence of atypia is highly reassuring [2].
  • Myoepithelial Pattern: The pathologist may use special stains to check the cell layers. An intact myoepithelial layer supports a benign diagnosis [19][18].
  • Mitotic Activity: Mitoses indicate dividing cells. While high levels are concerning, an occasional mitosis can occur in perfectly benign lesions, especially during lactation. It is evaluated in context with the rest of the tissue.

If your report mentions an “indeterminate fibroepithelial lesion” or “increased stromal cellularity,” your doctor may want to evaluate you further to rule out a phyllodes tumor, a different type of growth that sometimes requires surgical removal [14].

Common questions in this guide

How is a breast adenoma evaluated after a lump is found?
Evaluation usually starts with ultrasound or diagnostic mammography based on age and the lump’s features. If imaging is suspicious or the diagnosis is uncertain, a core needle biopsy provides tissue for microscopic examination.
What do BI-RADS 3 and BI-RADS 4 mean?
BI-RADS 3 means an imaging finding is probably benign, with less than a 2% chance of cancer, and short-interval follow-up imaging is usually recommended. BI-RADS 4 means the finding is suspicious and generally requires a biopsy, although the category covers a wide range of cancer risk.
Why is a core needle biopsy used instead of a fine-needle aspiration?
A core needle biopsy removes small cylinders of tissue, allowing the pathologist to examine how the cells are arranged. Fine-needle aspiration removes individual cells, so it provides less information about the tissue’s overall architecture.
What does it mean if my biopsy and imaging are concordant?
Radiologic-pathologic concordance means the tissue diagnosis adequately explains what was seen on the scan and that the sample appears representative. When a benign tubular adenoma matches a benign-appearing mass, routine monitoring may be appropriate; if the findings do not match, repeat biopsy or surgical removal may be recommended.
What pathology findings support a benign tubular adenoma?
Absence of atypical cells and an intact myoepithelial layer support a benign diagnosis. The pathologist also interprets mitotic activity in context, because an occasional dividing cell can occur in a benign lesion, especially during lactation.
Can a benign breast biopsy still need additional evaluation?
Yes, especially when imaging is highly suspicious, the sample may have missed a heterogeneous area, or a lump continues to grow. Your doctor may recommend another biopsy or surgical removal to make sure the tissue result explains the imaging finding.
What does an indeterminate fibroepithelial lesion mean on a breast biopsy?
This wording means the biopsy has not fully classified the growth. Increased stromal cellularity may lead to further evaluation for a phyllodes tumor, which sometimes requires surgical removal.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on breast adenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the BI-RADS score on my imaging report, and how does it relate to my biopsy results?
  2. 2.Is the pathology result 'concordant' with what you saw on the ultrasound or mammogram?
  3. 3.Does my pathology report show any high-risk or atypical features?
  4. 4.Why was a core needle biopsy chosen over a fine needle aspiration in my case?
  5. 5.If the biopsy showed a benign adenoma but the lump continues to grow, what are the next steps for evaluation?

References

References (19)
  1. 1

    Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging.

    Evans A, Trimboli RM, Athanasiou A, et al.

    Insights into imaging 2018; (9(4)):449-461 doi:10.1007/s13244-018-0636-z.

    PMID: 30094592
  2. 2

    Breast Lesions during Pregnancy - a Diagnostic Challenge: Case Report.

    Beyer I, Mutschler N, Blum KS, Mohrmann S

    Breast care (Basel, Switzerland) 2015; (10(3)):207-10 doi:10.1159/000381823.

    PMID: 26557826
  3. 3

    Imaging manifestations of ductal adenoma of the breast: A case report.

    Zhu Y, Yu H, Zheng Z, et al.

    Open life sciences 2024; (19(1)):20220917 doi:10.1515/biol-2022-0917.

    PMID: 39022161
  4. 4

    Common Breast Problems.

    Salzman B, Collins E, Hersh L

    American family physician 2019; (99(8)):505-514.

    PMID: 30990294
  5. 5

    [Mammography-Guided Interventional Procedure].

    Choi WJ, Kim HH

    Journal of the Korean Society of Radiology 2023; (84(2)):320-331 doi:10.3348/jksr.2022.0145.

    PMID: 37051394
  6. 6

    Tomosynthesis-detected Architectural Distortion: Management Algorithm with Radiologic-Pathologic Correlation.

    Durand MA, Wang S, Hooley RJ, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(2)):311-21 doi:10.1148/rg.2016150093.

    PMID: 26963448
  7. 7

    An audit of the results of ultrasound-guided core needle biopsy of mammography versus ultrasound screen-detected breast lesions.

    Rhee SJ, Han BK, Ko ES, et al.

    Journal of clinical ultrasound : JCU 2017; (45(5)):261-266 doi:10.1002/jcu.22454.

    PMID: 28182285
  8. 8

    Understanding BI-RADS Category 3.

    Fazeli S, Stepenosky J, Guirguis MS, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(1)):e240169 doi:10.1148/rg.240169.

    PMID: 39636752
  9. 9

    Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.

    Berg WA, Berg JM, Sickles EA, et al.

    Radiology 2020; (296(1)):32-41 doi:10.1148/radiol.2020192641.

    PMID: 32427557
  10. 10

    MRI in the Assessment of BI-RADS® 4 lesions.

    Leithner D, Wengert G, Helbich T, et al.

    Topics in magnetic resonance imaging : TMRI 2017; (26(5)):191-199 doi:10.1097/RMR.0000000000000138.

    PMID: 28961568
  11. 11

    [Breast Imaging Reporting and Data System (BI-RADS): Advantages and Limitations].

    Choi JS

    Journal of the Korean Society of Radiology 2023; (84(1)):3-14 doi:10.3348/jksr.2022.0142.

    PMID: 36818717
  12. 12

    Clinical Significance of Fine Needle Aspiration in Managing Patients with Breast Lesions.

    Dinas K, Pratilas GC, Nasioutziki M, et al.

    Folia medica 2018; (60(3)):364-372.

    PMID: 30355841
  13. 13

    Evaluation of Breast Lump - Comparison between True-cut Needle Biopsy and FNAC in MMCH: A Study of 100 Cases.

    Kamal MZ, Banu NR, Alam MM, et al.

    Mymensingh medical journal : MMJ 2020; (29(1)):48-54.

    PMID: 31915335
  14. 14

    Benign phyllodes tumor with tubular adenoma-like epithelial component in FNAC: A diagnostic pitfall.

    Panda KM

    Journal of cytology 2016; (33(4)):224-226 doi:10.4103/0970-9371.190456.

    PMID: 28028339
  15. 15

    Mimickers of breast malignancy: imaging findings, pathologic concordance and clinical management.

    Guirguis MS, Adrada B, Santiago L, et al.

    Insights into imaging 2021; (12(1)):53 doi:10.1186/s13244-021-00991-x.

    PMID: 33877461
  16. 16

    Breast tubular adenoma: diagnostic challenges and management insights from a six-case series.

    Ng WR, Pellegrino S, Macindoe C, et al.

    Journal of surgical case reports 2026; (2026(9)):rjag865 doi:10.1093/jscr/rjag865.

    PMID: 42813196
  17. 17

    Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions.

    Zouzos A, Fredriksson I, Foukakis T, et al.

    Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13122897.

    PMID: 41462910
  18. 18

    Tubular Adenoma of the Breast: Radiologic-Pathologic Correlation.

    Joo GJ, Carter GJ, Berg WA

    Journal of breast imaging 2023; (5(6)):703-711 doi:10.1093/jbi/wbad066.

    PMID: 38141235
  19. 19

    Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.

    Ingyin H, Solomon JP, Li Y, et al.

    Histopathology 2026; (88(6)):1229-1235 doi:10.1111/his.70082.

    PMID: 41456879

This page is for informational purposes only and does not constitute medical advice. A radiologist, pathologist, or breast specialist should interpret your imaging and biopsy results and advise you about next steps.